Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, announced the successful completion of a $41 million Series A financing that included participation from five new investors - Eli Lilly and Company, Biovision Ventures, Pappas Capital, Hengdian Group Capital, and The Leukemia & Lymphoma Society Therapy Acceleration Program - as well as continued support from existing Solu investors Longwood Fund, DCVC Bio, Sante Ventures, Astellas Venture Management, and Alexandria Venture Investments.